First-of-its-kind study offers early indication of factors linked to increased odds of success for patients out of options.

Study results underline the importance of treating hepatitis C virus.

Investigators wanted to see if blinatumomab could increase survival rates free from leukemia and be less toxic than intensive chemotherapy.

90% to 100% of study participants achieved complete or partial responses to treatment.

Calquence is the second therapy approved under a new program that lets companies simultaneously apply for approval in multiple countries.